A substantial advancement in blood sugar treatment is emerging with the approval of tirzepatide at a dosage of 45mg. This new offering builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, and delivers a potentially greater benefit for individuals with diabetes of type 2. Clinical studies have indicated that the higher do… Read More